Novartis isn’t messing around with CAR-T, and it has a promising next-gen therapy to help prove it
The center ring at ASCO this weekend will feature CTL019, Novartis’ lead CAR-T that appears to be headed to a landmark approval in a matter …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
